Drug Development
Infigratinib topped “even the most optimistic expectations” for efficacy and safety in the late-stage PROPEL 3 study in achondroplasia, Truist Securities analysts said Thursday.
FEATURED STORIES
Analysts, investors and scientists are eager for Biogen’s 2026 BIIB080 readout. Even if successful, executives warn that there are many more steps before the Alzheimer’s therapy could reach the market.
With a clutch of key data and planned regulatory applications this year from Avidity Biosciences, REGENXBIO and Capricor Therapeutics, CureDuchenne CSO Michael Kelly sees “momentum” in the Duchenne muscular dystrophy pipeline, as Sarepta’s Elevidys leaves the door open.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
The FDA approved Pluvicto (targeted radioligand therapy) for use in adults with PSMA-positive mCRPC that has already metastasized to other body parts.
BioAge Labs presented new data demonstrating how its drug candidate BGE-175 is uniquely poised to tackle age-related immune system decline that leads to disease progression.
The 4D pharma has shared positive interim results from its Phase I/II study of a combination therapeutic for the treatment of renal cell carcinoma (RCC).
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
A man paralyzed from amyotrophic lateral sclerosis (ALS) now has the ability to spell out his thoughts, thanks to an implanted electrode device that reads his brain signals.
Pfizer is lining up a potential New Drug Application for an ulcerative colitis treatment for patients who are not seeing an improvement in their condition from currently available options.
Neurana Pharmaceuticals is facing dire financial straits following the failure of its Phase III treatment for muscle spasm relief associated with an acute, painful musculoskeletal condition.
Moderna reported positive interim results from the Phase II/III KidCOVE trial of its mRNA COVID-19 vaccine for children six months to under two years and two to six years of age.
Data from the Phase III study showed that efgartigimod achieved the primary endpoint of total IgG reduction from the baseline on the 29th day of observation.
Locus Biosciences’ CRISPR-Cas3-enhanced bacteriophage (crPhage™) product attacks harmful bacteria in the microbiome while sparing human cells.